We started 2021 by announcing strong
Full-Year 2020 results.
We were recognized by Ethisphere® as one of the world's most ethical companies in 2021.
We announced CHF 200 million investment in a new small molecule manufacturing complex in Visp (CH).
We announced a CHF 850 million investment to build two new state-of-the-art mammalian facilities in Visp (CH) and Portsmouth (US).
We expanded our collaboration with Moderna to double the drug substance production for its Spikevax COVID-19 vaccine in Visp (CH).
We announced further collaboration with Moderna for the installation of a new drug substance production line at our site in Geleen (NL).
We announced new investments in GMP laboratories and mid-scale manufacturing assets at our API manufacturing center in Nansha (CN).
We completed the divestment of our Specialty Ingredients business.
We reported continued strong momentum in H1 2021, with 14.7% CER sales growth and 33.3% CORE EBITDA margin
We extended our collaboration with a major biopharmaceutical partner for large-scale monoclonal antibody commercial supply.
We announced an investment to establish drug product manufacturing capabilities at our site in Guangzhou (CN).
We invested to expand drug product development and manufacturing services in Switzerland.
We announced an expansion of mammalian development services in Singapore.
At our Capital Markets Day 2021, we outlined strategic priorities and innovation highlights with a clear focus on sustainable value creation.
We expanded our exosomes manufacturing offering by adding two sites to our network: Codiak Bioscience’s exosome manufacturing site in Lexington (US); and Exosomics’ Service Unit located in Siena (IT).
We invested to expand microbial development laboratories at our Visp (CH) site by 50%.
We welcomed our new Chief Financial Officer - Philippe Deecke.
